Non-Human Primate Ebola Favipiravir Antiviral Clinical Trial (NHP E-FACT)
The main objective of workpackage 3 will be to establish whether Favipiravir can demonstrate efficacy in a non-human primate (NHP) model for Ebola:
- to prevent EBOV infection, when given as a prophylaxis
- to improve survival, when given during the incubation period
- to improve survival, when given during the symptomatic stage of infection, focusing on the earliest clinical stages.
Secondary objectives will be to identify modifications of biological parameters along the infection. This includes viral load and the evolution of viral populations at the molecular level, medical biochemistry and haematology parameters, immunological response.
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (Germany):
Prof. Stephan Günther (WP lead)
UNIVERSITE D'AIX MARSEILLE (France):
Prof. Xavier De Lamballerie (WP co-lead)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM):
Prof. Hervé Raoul
INSTITUT PASTEUR (France):
Dr. Sylvain Baize
DEPARTMENT OF HEALTH (UK):
Prof. Miles Carroll